Altos Labs disease first clinical path

This forces Altos to behave like a disease biotech first, and a longevity platform second. The company cannot ask regulators to approve healthier aging in general, so it needs an initial program where decline is visible on scans, lab values, or functional tests within a normal trial window. That makes fibrosis, osteoarthritis, and optic or immune tissues attractive, because each offers a concrete organ, a measurable readout, and a path to reuse assay and dosing know how in adjacent diseases.

• Fibrosis is a practical entry point because Altos already tied its mesenchymal drift work to liver, kidney, lung, and heart disease, and because fibrosis can be tracked with tissue biomarkers, imaging, and organ function measures rather than waiting years for a broad aging outcome.
  1 sacra 2 fda 3 fda
• Dorian gives Altos a second route into the clinic. Small molecules for lung fibrosis and osteoarthritis are simpler to dose, stop, and adjust than gene therapy, which matters for an area where the safe exposure window is still being mapped.
  1 sacra 2 fda
• The clearest regulatory proof point in the field already follows this playbook. Life Biosciences won FDA IND clearance for ER-100 in optic neuropathies in January 2026 and dosed its first patient in June 2026, using a named disease and visual endpoints rather than aging itself.
  1 sacra 4 lifebiosciences 5 lifebiosciences

If Altos can show benefit in one organ with a clean safety package, the business starts to compound. Success would turn aging biology from a broad scientific idea into a repeatable drug development template, where the next liver, lung, eye, or immune program is cheaper and faster to advance than the first.